Systematic analysis reveals immunogenic potential of cancer vaccines in digestive cancers, suggesting clinical trials need optimization.
Cancer vaccines, particularly nucleic acid and peptide vaccines, demonstrate potential as therapeutic interventions for digestive system cancers. Nucleic acid vaccines offer advantages in scalability and rapid design; however, they face limitations in delivery efficiency and immune activation. In contrast, peptide vaccines are safer and more stable than nucleic acid ones; however, they often elicit comparatively weaker immune responses. Therefore, it is essential to address platform-specific challenges. Future clinical trials should be strategically designed to evaluate and optimize these distinct platforms to accelerate their translation to clinical applications.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: